Antisense Drug Against BCL-2 Effective in Animal Cancer Models
SAN DIEGO--Genta Incorporated's antisense oligonucleotide targeted against the BCL-2 gene has proved effective against drug-resistant cancers in certain animal models of follicular lymphoma and colon cancer, the company said.
SAN DIEGO--Genta Incorporated's antisense oligonucleotide targetedagainst the BCL-2 gene has proved effective against drug-resistantcancers in certain animal models of follicular lymphoma and coloncancer, the company said.
The BCL-2 gene is overexpressed in many tumors, preventing normalapoptosis and inducing drug resistance. A phase I/II trial indrug-resistant follicular lymphoma is scheduled to begin at TheRoyal Marsden Hospital, London, by mid-year.
Articles in this issue
First Results of Avicidin Trials
Chemo Patients Often Develop Menstrual Irregularities
Growth Factor Receptor Blockade Moving From Laboratory to Clinic
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation
Vinorelbine Plus Chemo Promising in Advanced Disease
Bone Substudy a Part of Tamoxifen Prevention Trial
Ultrasound Breast Screens Useful in Selected Women
New Roles Forecast for Endocrine Therapy
Antisense Drug Against BCL-2 Effective in Animal Cancer Models
Anticancer Drugs From Zeneca in Regulatory Phase of Development
Osteosarcoma Chemo Regimens Debated
Primary Chemotherapy Allows Breast-Conserving Surgery in French Study
Cancer Care, Inc. Sponsors Make-Up Clinics for Chemo Patients
$2 Billion Budget for NCI Proposed
Risk of Gyn Cancer Increases After Diagnosis of Breast Cancer
Related Videos
Related Content
